HRP20040850A2 - Conjugates of biologically active compounds, methods for their preparation and use formulation and pharmaceutical applications thereof - Google Patents
Conjugates of biologically active compounds, methods for their preparation and use formulation and pharmaceutical applications thereofInfo
- Publication number
- HRP20040850A2 HRP20040850A2 HR20040850A HRP20040850A HRP20040850A2 HR P20040850 A2 HRP20040850 A2 HR P20040850A2 HR 20040850 A HR20040850 A HR 20040850A HR P20040850 A HRP20040850 A HR P20040850A HR P20040850 A2 HRP20040850 A2 HR P20040850A2
- Authority
- HR
- Croatia
- Prior art keywords
- alkyl
- alkenyl
- aryl
- alkynyl
- heteroaryl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pathology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35743402P | 2002-02-15 | 2002-02-15 | |
| PCT/US2003/004609 WO2003070174A2 (en) | 2002-02-15 | 2003-02-14 | Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20040850A2 true HRP20040850A2 (en) | 2005-08-31 |
Family
ID=27757618
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20040850A HRP20040850A2 (en) | 2002-02-15 | 2003-02-14 | Conjugates of biologically active compounds, methods for their preparation and use formulation and pharmaceutical applications thereof |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20050171342A1 (de) |
| EP (1) | EP1483277A4 (de) |
| AU (1) | AU2003219770B2 (de) |
| CA (1) | CA2476423A1 (de) |
| HR (1) | HRP20040850A2 (de) |
| IL (1) | IL163552A (de) |
| NZ (1) | NZ535354A (de) |
| WO (1) | WO2003070174A2 (de) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3945985B2 (ja) * | 2000-12-28 | 2007-07-18 | 株式会社リコー | デジタルカメラ装置 |
| HRP20010018A2 (en) | 2001-01-09 | 2002-12-31 | Pliva D D | Novel anti-inflammatory compounds |
| WO2003020702A2 (en) | 2001-08-31 | 2003-03-13 | The Rockefeller University | Phosphodiesterase activity and regulation of phosphodiesterase 1-b-mediated signaling in brain |
| EP1483579A4 (de) * | 2002-02-15 | 2006-07-12 | Merckle Gmbh | Konjugate biologisch aktiver verbindungen, verfahren zu ihrer herstellung und verwendung, formulierung und pharmazeutische anwendungen davon |
| WO2003070254A1 (en) * | 2002-02-15 | 2003-08-28 | Sympore Gmbh | Antibiotic conjugates |
| NZ537716A (en) * | 2002-07-08 | 2007-05-31 | Glaxosmithkline Zagreb | Novel nonsteroidal anti-inflammatory substances, compositions and methods for their use |
| EP1551865B1 (de) * | 2002-07-08 | 2009-04-22 | GlaxoSmithKline istrazivacki centar Zagreb d.o.o. | Hybridmoleküle von makroliden mit steroidalen/nicht-steroidalen antientzündlich aktiven molekülen |
| AU2003255851B2 (en) * | 2002-07-08 | 2009-07-23 | Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. | New compounds, compositions and methods for treatment of inflammatory diseases and conditions |
| AR043050A1 (es) | 2002-09-26 | 2005-07-13 | Rib X Pharmaceuticals Inc | Compuestos heterociclicos bifuncionales y metodos para preparar y usar los mismos |
| HRP20030324A2 (en) | 2003-04-24 | 2005-02-28 | Pliva-Istra�iva�ki institut d.o.o. | Compounds of antiinflammatory effect |
| WO2005042554A1 (en) * | 2003-10-30 | 2005-05-12 | Rib-X Pharmaceuticals, Inc. | Bifunctional macrolide heterocyclic compounds and methods of making and using the same |
| JP2007512256A (ja) * | 2003-11-18 | 2007-05-17 | リブ−エックス ファーマシューティカルズ，インコーポレイテッド | 二官能性マクロライド複素環化合物ならびにこれらを製造する方法およびこれらを使用する方法 |
| EP2716647A3 (de) | 2004-02-27 | 2014-08-20 | Rib-X Pharmaceuticals, Inc. | Makrocyclische Verbindungen Und Verfahren Zu Deren Herstellung Und Anwendung |
| US20060116336A1 (en) * | 2004-03-17 | 2006-06-01 | American Pharmaceutical Partners, Inc. | Lyophilized azithromycin formulation |
| US7468428B2 (en) * | 2004-03-17 | 2008-12-23 | App Pharmaceuticals, Llc | Lyophilized azithromycin formulation |
| US20060183696A1 (en) * | 2004-08-12 | 2006-08-17 | Pliva-Istrazivacki Institut D.O.O. | Use of immune cell specific conjugates for treatment of inflammatory diseases of gastrointestinal tract |
| RU2007108544A (ru) * | 2004-08-12 | 2008-09-20 | Глаксосмитклайн Истраживацки Центар Загреб Д.О.О.(Hr) | Применение клеточно-специфических конъюгатов для лечения воспалительных заболеваний желудочно-кишечного тракта |
| US7767797B1 (en) | 2004-09-30 | 2010-08-03 | Synovo Gmbh | Macrocyclic compounds and methods of use thereof |
| GB0421908D0 (en) * | 2004-10-01 | 2004-11-03 | Angeletti P Ist Richerche Bio | New uses |
| US20090048221A1 (en) * | 2004-10-27 | 2009-02-19 | Mladen Mercep | Conjugates with Anti-Inflammatory Activity |
| EP1846428A1 (de) * | 2005-01-14 | 2007-10-24 | GlaxoSmithKline istrazivacki centar Zagreb d.o.o. | Entzündungshemmende konjugate von makroliden und cumarinen |
| WO2006133261A2 (en) | 2005-06-06 | 2006-12-14 | Intra-Cellular Therapies, Inc. | Organic compounds |
| CA2615581A1 (en) * | 2005-07-26 | 2007-02-01 | Merckle Gmbh | Macrolide conjugates of pyrrolizine and indolizine compounds as inhibitors of 5-lipooxygenase and cyclooxygenase |
| EP1946102A1 (de) * | 2005-07-27 | 2008-07-23 | University Of Southern California | Aminosäuren auf coumarinbasis zur verwendung in enzymaktivitäts- und substratspezifitätstests |
| US20080194592A1 (en) * | 2005-08-23 | 2008-08-14 | Intra-Cellular Therapies, Inc. | Organic Compounds |
| EP2077271A4 (de) | 2006-05-01 | 2010-09-15 | Taisho Pharmaceutical Co Ltd | Makrolitderivat |
| US9198924B2 (en) * | 2006-11-13 | 2015-12-01 | Intra-Cellular Therapies, Inc. | Organic compounds |
| EP2089034A4 (de) | 2006-12-05 | 2010-07-28 | Intra Cellular Therapies Inc | Neue verwendungszwecke |
| JP2012516305A (ja) * | 2009-01-30 | 2012-07-19 | グラクソ グループ リミテッド | 好中球優位の炎症性疾患の治療のための９−デオキソ−９ａ−メチル−９ａ−アザ−９ａ−ホモエリスロマイシンａ誘導体 |
| EP2400970A4 (de) | 2009-02-25 | 2012-07-18 | Intra Cellular Therapies Inc | Pde-1-hemmer für augenleiden |
| US9468637B2 (en) | 2009-05-13 | 2016-10-18 | Intra-Cellular Therapies, Inc. | Organic compounds |
| JP6166534B2 (ja) | 2009-08-05 | 2017-07-19 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 新規調節タンパク質および阻害剤 |
| CA2814333A1 (en) * | 2010-10-10 | 2012-04-19 | Synovo Gmbh | Anti-inflammatory macrolides |
| WO2013148874A1 (en) | 2012-03-27 | 2013-10-03 | Burnet Michael W | Anti-inflammatory macrolides |
| KR20220051197A (ko) | 2012-05-17 | 2022-04-26 | 익스텐드 바이오사이언시즈, 인크. | 개선된 약물 전달용 캐리어 |
| WO2014127331A1 (en) | 2013-02-17 | 2014-08-21 | Intra-Cellular Therapies, Inc. | Novel uses |
| US9598426B2 (en) | 2013-03-15 | 2017-03-21 | Intra-Cellular Therapies, Inc. | Organic compounds |
| US9545406B2 (en) | 2013-03-15 | 2017-01-17 | Intra-Cellular Therapies, Inc. | Method of treating a CNS injury with a PDE1 inhibitor |
| US9884872B2 (en) | 2014-06-20 | 2018-02-06 | Intra-Cellular Therapies, Inc. | Organic compounds |
| US10285992B2 (en) | 2014-08-07 | 2019-05-14 | Intra-Cellular Therapies, Inc. | Combinations of PDE1 inhibitors and NEP inhibitors and associated methods |
| DK3177627T3 (da) | 2014-08-07 | 2019-10-21 | Intra Cellular Therapies Inc | Imidazo[1,2-a]-pyrazolo[4,3-e]-pyrimidin-4-on-derivater med pde1-hæmmende aktivitet |
| IL292225B2 (en) | 2014-09-17 | 2024-12-01 | Intra Cellular Therapies Inc | Derivatives of 5,7,7-trimethyl-[2H]-imidazo-[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5H)-one and pharmaceutical compositions comprising them. |
| WO2016065052A1 (en) | 2014-10-22 | 2016-04-28 | Extend Biosciences, Inc. | Insulin vitamin d conjugates |
| US9585934B2 (en) | 2014-10-22 | 2017-03-07 | Extend Biosciences, Inc. | Therapeutic vitamin D conjugates |
| US9789197B2 (en) | 2014-10-22 | 2017-10-17 | Extend Biosciences, Inc. | RNAi vitamin D conjugates |
| GB201520419D0 (en) | 2015-11-19 | 2016-01-06 | Epi Endo Pharmaceuticals Ehf | Compounds |
| US10682354B2 (en) | 2016-03-28 | 2020-06-16 | Intra-Cellular Therapies, Inc. | Compositions and methods |
| EP3970719A1 (de) | 2016-09-12 | 2022-03-23 | Intra-Cellular Therapies, Inc. | Pde1-inhibitor zur verwendung in einem verfahren zur behandlung oder prophylaxe von entzündungen und/oder einer entzündlichen krankheit oder störung |
| JP7401442B2 (ja) | 2018-01-31 | 2023-12-19 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 新規使用 |
| AU2020259997B2 (en) * | 2019-04-18 | 2025-08-07 | Azura Ophthalmics Ltd. | Compounds and methods for the treatment of ocular disorders |
| EP4025202A4 (de) | 2019-09-03 | 2023-08-02 | Intra-Cellular Therapies, Inc. | Neuartige verbindungen |
| US12364695B2 (en) | 2020-06-02 | 2025-07-22 | Intra-Cellular Therapies, Inc. | Methods of treating inflammatory disease |
| WO2023248010A2 (en) | 2022-06-23 | 2023-12-28 | Synovo Gmbh | Targeted modulators of jak3 for treatment of inflammatory and autoimmune diseases |
| EP4593867A2 (de) | 2022-09-30 | 2025-08-06 | Extend Biosciences, Inc. | Langwirkendes parathormon |
| GB202404587D0 (en) | 2024-03-28 | 2024-05-15 | Epiendo Pharmaceuticals Ehf | Chemical forms |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3417077A (en) | 1966-05-16 | 1968-12-17 | Lilly Co Eli | Erythromycin derivative and process for the preparation thereof |
| US4375414A (en) | 1971-05-20 | 1983-03-01 | Meir Strahilevitz | Immunological methods for removing species from the blood circulatory system and devices therefor |
| US3884903A (en) * | 1973-06-21 | 1975-05-20 | Abbott Lab | 4{41 -Deoxy-4{41 -oxoerythromycin B derivatives |
| EP0044090A3 (de) | 1978-10-02 | 1982-05-12 | Merck & Co. Inc. | Lysosomotropische therapeutische Detergentia, sie enthaltende Mischungen und ihre Anwendung |
| SI7910768A8 (en) * | 1979-04-02 | 1996-06-30 | Pliva Pharm & Chem Works | Process for pripering 11-aza-4-0-cladinosyl-6-0-desosaminyl-15-ethyl- 7,13,14-trihydroxy-3,5,7,9,12,14-hexamethyl- oxacyclopentadecane-2-one and their derivatives |
| SI8110592A8 (en) | 1981-03-06 | 1996-06-30 | Pliva Pharm & Chem Works | Process for preparing of n-methyl-11-aza-10-deoxo-10-dihydroerythromycine a and derivatives thereof |
| US4382086A (en) | 1982-03-01 | 1983-05-03 | Pfizer Inc. | 9-Dihydro-11,12-ketal derivatives of erythromycin A and epi-erythromycin A |
| US4474768A (en) * | 1982-07-19 | 1984-10-02 | Pfizer Inc. | N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor |
| US4518590A (en) | 1984-04-13 | 1985-05-21 | Pfizer Inc. | 9α-Aza-9α-homoerythromycin compounds, pharmaceutical compositions and therapeutic method |
| US4585759A (en) | 1985-01-22 | 1986-04-29 | Pfizer Inc. | Antibacterial derivatives of a neutral macrolide |
| JPH0720857B2 (ja) | 1988-08-11 | 1995-03-08 | テルモ株式会社 | リポソームおよびその製法 |
| US5466681A (en) * | 1990-02-23 | 1995-11-14 | Microcarb, Inc. | Receptor conjugates for targeting penicillin antibiotics to bacteria |
| US5405975A (en) * | 1993-03-29 | 1995-04-11 | Molecular Probes, Inc. | Fluorescent ion-selective diaryldiaza crown ether conjugates |
| SI9011409A (en) | 1990-07-18 | 1995-10-31 | Pliva Pharm & Chem Works | O-methyl azitromycin derivates, methods and intermediates for their preparation and methods for preparation of pharmaceuticals products which comprise them |
| JPH07103148B2 (ja) | 1991-12-16 | 1995-11-08 | 株式会社ディ・ディ・エス研究所 | アントラサイクリン−マクロライド複合体 |
| US20030068362A1 (en) | 1993-02-22 | 2003-04-10 | American Bioscience, Inc. | Methods and formulations for the delivery of pharmacologically active agents |
| US5486536A (en) * | 1994-08-15 | 1996-01-23 | The Regents Of The University Of Michigan | Sulfatides as anti-inflammatory compounds |
| US5750493A (en) * | 1995-08-30 | 1998-05-12 | Raymond F. Schinazi | Method to improve the biological and antiviral activity of protease inhibitors |
| FR2738571B1 (fr) * | 1995-09-11 | 1997-10-17 | Roussel Uclaf | Nouveaux derives de la 5-0-desosaminyl 6-0-methyl- erythronolide a, leur procede de preparation et leur application a la preparation de produits biologiquement actifs |
| WO1997041255A1 (en) * | 1996-04-26 | 1997-11-06 | Massachusetts Institute Of Technology | Three-hybrid screening assay |
| AU5775698A (en) | 1996-12-30 | 1998-07-31 | Governors Of The University Of Alberta, The | Mammalian equilibrative nucleoside transporters |
| US5827533A (en) * | 1997-02-06 | 1998-10-27 | Duke University | Liposomes containing active agents aggregated with lipid surfactants |
| EP0895999A1 (de) * | 1997-08-06 | 1999-02-10 | Pfizer Products Inc. | C-4"-substituierte Macrolidantibiotica |
| PT1437359E (pt) | 1997-10-16 | 2007-04-30 | Glaxosmithkline Zagreb | Novos 3,6-hemicetais da classe dos 9a-azalidos |
| HRP980189B1 (en) | 1998-04-06 | 2004-04-30 | Pliva Pharm & Chem Works | Novel 15-membered lactams ketolides |
| AU4549999A (en) | 1998-06-08 | 1999-12-30 | Advanced Medicine, Inc. | Novel polyene macrolide compounds and uses |
| AU4543799A (en) | 1998-06-08 | 1999-12-30 | Theravance, Inc. | Combinatorial synthesis of multibinding libraries |
| AU4543899A (en) | 1998-06-08 | 1999-12-30 | Advanced Medicine, Inc. | Multibinding inhibitors of microsomal triglyceride transferase protein |
| US6043227A (en) * | 1998-08-19 | 2000-03-28 | Pfizer Inc. | C11 carbamates of macrolide antibacterials |
| US6100240A (en) | 1998-10-09 | 2000-08-08 | Pfizer Inc | Macrolide derivatives |
| MXPA02001857A (es) | 1999-08-24 | 2003-07-14 | Cellgate Inc | Composiciones y metodos para incrementar la entrega de drogas a traves y dentro de tejidos epiteliales. |
| WO2001020331A1 (en) | 1999-09-14 | 2001-03-22 | Xenoport, Inc. | Substrates and screening methods for transport proteins |
| ID27331A (id) | 1999-09-29 | 2001-03-29 | Pfizer Prod Inc | Pembuatan antibiotik-antibiotik ketolida karbamat |
| JP2003519662A (ja) * | 2000-01-14 | 2003-06-24 | イントラバイオティクス ファーマシューティカルズ，インコーポレイテッド | ポリエン・マクロライド誘導体並びにその製法及び使用 |
| EP1122261A3 (de) | 2000-01-31 | 2001-09-26 | Pfizer Products Inc. | 13- und 14-Gliederige Antibakterielle-Makroliden |
| TR200401847T4 (tr) | 2000-06-30 | 2004-09-21 | Pfizer Products Inc. | Makrolit antibiyotikler. |
| HRP20010018A2 (en) | 2001-01-09 | 2002-12-31 | Pliva D D | Novel anti-inflammatory compounds |
| JP2005510534A (ja) | 2001-11-21 | 2005-04-21 | アクティブバイオティクス インコーポレイティッド | 標的化治療薬およびその使用 |
| WO2003070254A1 (en) | 2002-02-15 | 2003-08-28 | Sympore Gmbh | Antibiotic conjugates |
| EP1483579A4 (de) * | 2002-02-15 | 2006-07-12 | Merckle Gmbh | Konjugate biologisch aktiver verbindungen, verfahren zu ihrer herstellung und verwendung, formulierung und pharmazeutische anwendungen davon |
| AU2003255851B2 (en) * | 2002-07-08 | 2009-07-23 | Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. | New compounds, compositions and methods for treatment of inflammatory diseases and conditions |
-
2003
- 2003-02-14 WO PCT/US2003/004609 patent/WO2003070174A2/en not_active Ceased
- 2003-02-14 NZ NZ535354A patent/NZ535354A/en unknown
- 2003-02-14 US US10/504,787 patent/US20050171342A1/en not_active Abandoned
- 2003-02-14 HR HR20040850A patent/HRP20040850A2/hr not_active Application Discontinuation
- 2003-02-14 CA CA002476423A patent/CA2476423A1/en not_active Abandoned
- 2003-02-14 EP EP03716044A patent/EP1483277A4/de not_active Withdrawn
- 2003-02-14 US US10/367,105 patent/US7579324B2/en not_active Expired - Fee Related
- 2003-02-14 AU AU2003219770A patent/AU2003219770B2/en not_active Ceased
-
2004
- 2004-08-15 IL IL163552A patent/IL163552A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| US20050171342A1 (en) | 2005-08-04 |
| WO2003070174A3 (en) | 2003-11-13 |
| US7579324B2 (en) | 2009-08-25 |
| EP1483277A4 (de) | 2007-10-03 |
| US20040087517A1 (en) | 2004-05-06 |
| WO2003070174A2 (en) | 2003-08-28 |
| NZ535354A (en) | 2008-01-31 |
| AU2003219770B2 (en) | 2008-10-09 |
| CA2476423A1 (en) | 2003-08-28 |
| IL163552A (en) | 2010-11-30 |
| AU2003219770A1 (en) | 2003-09-09 |
| EP1483277A2 (de) | 2004-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2003219770B2 (en) | Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof | |
| US8357506B2 (en) | Method of identifying improved conjugates of biologically active compounds | |
| van de Wetering et al. | Intestinal breast cancer resistance protein (BCRP)/Bcrp1 and multidrug resistance protein 3 (MRP3)/Mrp3 are involved in the pharmacokinetics of resveratrol | |
| Zhang et al. | Fuplatin: An efficient and low-toxic dual-prodrug | |
| Lee et al. | Azaindolylsulfonamides, with a more selective inhibitory effect on histone deacetylase 6 activity, exhibit antitumor activity in colorectal cancer HCT116 cells | |
| AU2020200143B2 (en) | Dendrimer compositions and use in treatment of necrotizing enterocolitis and other gastrointestinal disorders | |
| Lv et al. | Prostate-specific membrane antigen targeted therapy of prostate cancer using a DUPA–paclitaxel conjugate | |
| Gao et al. | Enhanced anti-inflammatory activity of peptide–gold nanoparticle hybrids upon cigarette smoke extract modification through TLR inhibition and autophagy induction | |
| Lelle et al. | Overcoming drug resistance by cell-penetrating peptide-mediated delivery of a doxorubicin dimer with high DNA-binding affinity | |
| Compain et al. | A β-glucuronidase-responsive albumin-binding prodrug for potential selective kinase inhibitor-based cancer chemotherapy | |
| WO2005027828A2 (en) | Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof | |
| Renoux et al. | A β-glucuronidase-responsive albumin-binding prodrug programmed for the double release of monomethyl auristatin E | |
| JP2023505438A (ja) | プロスタグランジン含有量を介してａｋｒ１ｃ３酵素の発現レベルと関連付ける方法、および薬剤投与のスクリーニングの使用 | |
| Liu et al. | Discovery of novel p53-MDM2 inhibitor (RG7388)-conjugated platinumiv complexes as potent antitumor agents | |
| Wang et al. | Novel NF-κB inhibitor-conjugated Pt (IV) prodrug to enable cancer therapy through ROS/ER stress and mitochondrial dysfunction and overcome multidrug resistance | |
| Choi et al. | Highly Sensitive Real-Time Monitoring of Adenosine Receptor Activities in Nonsmall Cell Lung Cancer Cells Using Carbon Nanotube Field-Effect Transistors | |
| Zyk et al. | Synthesis of Prostate-Specific Membrane Antigen-Targeted Bimodal Conjugates of Cytotoxic Agents and Antiandrogens and Their Comparative Assessment with Monoconjugates | |
| Krajčovičová et al. | A stepwise approach for the synthesis of folic acid conjugates with protein kinase inhibitors | |
| Lanza et al. | Cyclam glycoconjugates as lectin ligands and protective agents of metal-induced amyloid aggregation | |
| US20170246315A1 (en) | Therapeutic agents and use thereof | |
| Wei et al. | Fine-tuning phenoxy silyl scaffolds for the development of glutathione-responsive prodrugs and antibody–drug conjugates | |
| Ly et al. | Raman spectroscopy of pH-induced release of zidovudine from lactobionic acid-conjugated PEGylated gold colloids | |
| Parashar et al. | A clickable folic acid-rhamnose conjugate for selective binding to cancer cells | |
| US20200055934A1 (en) | Therapeutic agents and use thereof | |
| Li et al. | New CDDO Arylboronate Ester Derivatives with High Selectivity and Low Toxicity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| AIPI | Request for the grant of a patent on the basis of a substantive examination of a patent application | ||
| PPPP | Transfer of rights |
Owner name: MERCKLE GMBH, DE |
|
| ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20090213 Year of fee payment: 7 |
|
| OBST | Application withdrawn |